

# Appendix 4E

(Rule 4.3A)

## Preliminary final report

Name of entity

Nanoveu Limited	ABN: 97 624 421 085
-----------------	---------------------

### 1. Details of the Reporting Period and the Previous Corresponding Period

Financial period ended ("current period")	Financial period ended ("previous period")
31 December 2022	31 December 2021

### 2. Results for Announcement to the Market

					2022 \$'000
2.1	Revenue from ordinary activities	down	81%	to	160
2.2	Loss from ordinary activities after tax attributable to members	up	25%	to	2,707
2.3	Net loss for the period attributable to members	up	25%	to	2,707
2.4	Loss per share	flat		at	1.2 cents

2.5	<b>Brief explanation of results</b>
	<p><u>Antiviral Products:</u></p> <p>The Company continues to make progress in its line of antiviral products and has established trials in condominium properties, banks, education centres and over 11 commercial buildings in Singapore. In addition, the Company has commenced trials with a leading Singapore hospital group, focusing on Hospital Acquired Infection control.</p> <p>The Company has developed a new line of antimicrobial wellness products and within this category the Resoothe Wellness tape obtained TGA approval in Australia, in December 2022.</p> <p><u>Indian Joint Venture:</u></p> <p>During the half-year period the Company signed an agreement to distribution its products in India in the first quarter of 2023. During the past nine months, Nanoveu and its Indian partner, Alan Scott, have collectively targeted key accounts and hospitals in India to market Nanoveu's products, particularly on its air filters line of products and surface protection.</p>

For personal use only

	<p><u>EyeFyx Project:</u></p> <p>The Company diverted much of its technical resources into its Antiviral projects but continued development with its technology partner Nanyang Technology University (NTU) for its EyeFyx Project. Together with NTU, the Company intends to progress its current PCT patent filing into the USA.</p> <p><u>Successful Capital Raisings</u></p> <p>In October 2022, Nanoveu raised \$475,000 (before costs) through a placement to sophisticated and professional investors at \$0.01 per share (“Shares”). This was the first tranche of a two stage placement.</p> <p>Subsequent to year end, and following approval by shareholders, the second tranche of \$525,000 was raised from the issue of 52,500,000 shares at \$0.01 per share and 50,000,000 options with an exercise price of \$0.02 each on or before 26 January 2026.</p> <p>62 Capital Pty Ltd acted as the lead manager and subsequent to year end were issued 6,000,000 shares and 3,000,000 options with an exercise price of \$0.02 on or before 26 January 2026.</p> <p><u>Repayment of Equity Facility:</u></p> <p>Part of the proceeds from the capital raise have been and will be used to repay the amount outstanding to the investor under the funding agreement announced to the ASX on 14 August 2020, being \$626,000. \$326,000 of that amount was repaid by the Company on 4 November 2022, followed by five monthly instalments of \$60,000 each commencing in 2023.</p> <p>Nanoveu issued 7,500,000 options with an exercise price of \$0.02 and 4 October 2025 expiry to the investor in consideration for the variation of the agreement to permit repayment of the amount outstanding.</p> <p>For further details, please refer to the financial report.</p>
--	---

**3. NTA Backing**

	Current period	Previous corresponding period
Net tangible asset/(deficiency) backing per ordinary security	\$(0.001)	\$0.0076

**4 Control gained or lost over entities having material effect**

n/a

**5. Dividends**

There were no dividends declared or paid during the period and the do not recommend that any dividends be paid.

**6. Dividend Reinvestment Plans**

Not applicable.

**7. Material interest in entities which are not controlled entities**

Not applicable.

**8. Foreign Entities**

This report includes the following foreign subsidiaries:

- Nanoveu Pte Ltd, registered in Singapore; and
- Nanoveu Distribution Inc., registered in the United States of America.

**9. Annual Report**

Refer to the attached Annual Report for the year ended 31 December 2022 for further details. The financial statements contained in the annual report have been audited.

This report should be read in conjunction with the attached Annual Report for the year ended 31 December 2022.



Signed by:

Date: 28 February 2023

Name: Alfred Chong  
Managing Director & CEO

For personal use only

For personal use only



**nanoveu**  
TRUSTED ■ SUSTAINABLE ■ INNOVATION

**Nanoveu Limited**

(ACN 624 421 085)

**Annual Financial Report**  
for the year ended 31 December 2022

**Index**

Company Directory	2
Letter from the Chairman	3
Directors' Report	4
Auditor's Independence Declaration	11
Remuneration Report	12
Consolidated Statement of Profit or Loss and Other Comprehensive Income	20
Consolidated Statement of Financial Position	21
Consolidated Statement of Cash Flows	22
Consolidated Statement of Changes in Equity	23
Notes to the Consolidated Financial Statements	24
Directors' Declaration	49
Independent Auditor's Report	50
ASX Additional Information	54

## Company Directory

### Directors

Dr David Pevcic  
Non-executive Chairman

Mr Alfred Chong  
Managing Director

Mr Michael van Uffelen  
Executive Director

Mr Steven Apedaile  
Non-executive Director

### Company Secretary

Mr Michael van Uffelen

### Share Registry

Automic Registry Services  
Level 2  
267 St Georges Terrace  
Perth WA 6000

Telephone (within Australia): 1300 288 664  
Telephone (outside Australia): +61 2 9698 5414  
Email: [hello@automic.com.au](mailto:hello@automic.com.au)

### Registered Office

1/18 Olive Street  
Subiaco WA 6008

Tel: +61 8 6244 9095

### Web Address

[www.nanoveu.com](http://www.nanoveu.com)

### ASX Code:

NVU

### Auditors

BDO Audit (WA) Pty Ltd  
Level 9, Mia Yellagonga Tower 2  
5 Spring Street  
Perth WA 6000

### Solicitors

Steinepreis Paganin  
Level 4, The Read Buildings  
16 Milligan Street  
Perth WA 6000

## Letter from the Chairman

Dear Shareholders,

The 2022 Calendar Year has been an important period for Nanoveu, as we've continued to position ourselves as a global leader in the market, by advancing our portfolio of antiviral and antimicrobial technologies through ongoing product development, expansion of our international distribution channels.

I would like to thank the Nanoveu team for their ongoing dedication to date, as well as our loyal shareholders for their support.

We look forward to an exciting 2023 and another year of milestones for Nanoveu.

David Pevcic  
Non-executive Chairman

For personal use only

## Directors' Report

Your Directors submit the financial report of Nanoveu Limited (the Company or Nanoveu) for the year ended 31 December 2022.

### Directors

The names of directors who held office during or since the end of the financial period and until the date of this report are as follows. Directors were in office for the entire financial period unless otherwise stated.

<b>Name, qualifications, independence status and special responsibilities</b>	<b>Experience</b>
<p>Dr David Pevcic (BSc, MBBS, MAICD) Non-executive Chairman Appointed 3 February 2023</p>	<p>David is a medical doctor and businessman, with a principal focus on the resources and biotechnology sectors.</p> <p>He holds a Bachelor of Science, Bachelor of Medicine and Bachelor of Surgery from the University of Western Australia and is a Member of the Australian Institute of Company Directors. Furthermore, he is the author of multiple academic publications in the field of Neuroscience.</p> <p>Directorships in the past 3 years:</p> <ul style="list-style-type: none"> <li>- Battery Age Minerals Limited (2 February 2023 to present)</li> </ul>
<p>Mr Alfred Chong (BSc Comp Science, MBA) <i>Managing Director and CEO</i> Appointed 14 February 2018</p>	<p>Alfred is the Founder of Nanoveu. He has a history of building companies and executing trade sales in California and Singapore. Alfred moved back to Asia in 1997 and was the Asia Pacific CEO for Atex Media Command, a global provider of solutions and services to the media industry; CEO for THISS Technologies Inc, a satellite communications company; CEO for 121View, a digital signage company; and CMO at 3D International before founding Nanoveu.</p> <p>The Singapore American Business Association in the United States named Alfred Entrepreneur of the Year and the San Francisco Chronicle named Alfred as one of the twenty foreign-born high technology "visionaries" who have helped to make the San Francisco Bay Area the world's technology centre. Alfred received both his Bachelor of Science in Computer Science and his Master's in Business Administration from the University of San Francisco.</p> <p>Directorships in the past 3 years: None</p>
<p>Mr Michael van Uffelen (B Comm, ACA) <i>Director, CFO and Company Secretary</i> Appointed 14 February 2018</p>	<p>Michael is an experienced Director, CFO and Company Secretary actively engaged in managing companies and providing corporate advisory services.</p> <p>Michael holds a Bachelor of Commerce degree from the University of Western Australia and is a Chartered Accountant. He has over 30 years company and business management experience gained with major accounting firms, an investment bank, and private and public companies, in Australia and internationally.</p> <p>Directorships in the past 3 years:</p> <ul style="list-style-type: none"> <li>- Tian Poh Resources Limited (31 May 2015 to 31 May 2022)</li> <li>- Anson Resources Limited (18 October 2018 to present)</li> </ul>

## Directors' Report (continued)

### Name, qualifications, independence status and special responsibilities

### Experience

Mr Steven Apedaile

(FCA)

*Independent Non-executive Director*

Appointed 14 May 2018

Steven has worked in the accounting profession for over 30 years, 25 of which were spent in Hong Kong with the first 7 years with KPMG Hong Kong and then 18 years with Horwath Hong Kong. Steven has experience in all facets of international business, corporate finance and forensic accounting services.

Steven is the non-executive Chairman of Sprintex Limited and is a Fellow of the UK Institute of Chartered Accountants in England and Wales and is a Member of the Australian Institute of Company Directors.

ASX listed company directorships in the past 3 years:

- Sprintex Limited (16 April 2021 to present)

Mr Scott Beeton

*Non-executive Chairman*

Appointed 22 September 2021, resigned 31 August 2022

Scott has over 16 years' experience in leadership and senior management roles across financial services, technology and fintech ASX-listed companies. He has been a director on a number of ASX-listed companies as well as holding directorship and responsible manager/entity titles on various entities holding Australian Financial Services Licences.

Directorships in the past 3 years:

- TZ Limited (June 2021 to present)

Mr David Nicol

(BSc, MA, PhD)

*Independent Non-executive Director*

Appointed 17 July 2018, retired 2 March 2022

David is a seasoned director and advisor for technology-based companies. He currently serves on four boards, one privately held and three public, for which two of the latter he chairs the Audit Committees.

David has held executive positions with three public companies - Verisign, Illuminet, and United Telecom/Sprint - and six early-stage, private companies, all of which were subsequently acquired. Beyond P&L responsibilities, his leadership roles have included strategic planning, business development, acquisitions, business planning, operations planning, product management, product development/support, financial planning, and fund raising/IR. Earlier activities included management consulting (F100 enterprises), MBA-level business school professor and aeronautical engineering (LTV Aerospace, North Am. Aviation and Boeing).

ASX listed company directorships in the past 3 years: None

### Directors' interests

As at the date of this report, the interests of the Directors in the Company were:

	Number of Fully Paid Ordinary Shares	Number of Performance Rights	Number of 5.8c Unlisted Options Expiring 27 October 2023
David Pevcic	200,000	-	-
Alfred Chong	43,127,558	2,150,000	250,000
Michael van Uffelen	770,625	1,683,500	77,063
Steven Apedaile	1,000,350	155,000	100,035
Scott Beeton (resigned 31 August 2022)	-	-	-
David Nicol (retired 2 March 2022)	722,500	155,000	72,250

## Directors' Report (continued)

### Directors' Meetings

The number of meetings of Directors held during the financial period and the number of meetings attended by each Director was as follows:

Name	Number of meetings eligible to attend	Number of meetings attended
Alfred Chong	2	2
Michael van Uffelen	2	2
Steven Apedaile	2	2
Scott Beeton	2	2

Note: excludes David Pevcic who was appointed after period end.

### Company Secretary

The company secretary is Michael van Uffelen. Details are disclosed in director information.

### Dividends

No dividends have been paid or declared since the start of the financial period and the Directors do not recommend the payment of a dividend in respect of the financial period.

### Principal Activities

Nanoveu is a technology company developing a range of products for mobile phones and other digital displays. The Company's wholly-owned, flagship product is its Nanoshield antiviral protection which is available in a variety of mobile phone screen covers, mobile phone cases and as a commercial film capable of being applied to a number of surfaces. The product is a clear plastic containing a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. The product is commercially available and sold in a number of countries via Nanoveu's channel partners.

The antiviral protection business has expanded to include surface sprays for applications such as the prevention of algae and lichen growth on solar panels..

In addition, the Company is also developing the following products:

- Customskins: vending machines capable of precisely applying screen covers to mobile phones in just over a minute and with an alignment accuracy of 150 microns;
- EyeFyx: a vision correction solution under development using hardware and software to manipulate screen output; and
- Anti-reflective coating technology capable of being applied to mobile phones, tablets, automotive displays and other digital displays.

### Operating and financial review

#### *Review of Operations*

#### Antiviral Products:

The Company continues to make progress in its line of antiviral products and has established trials in condominium properties, banks, education centres and over 11 commercial buildings in Singapore. In addition, the Company has commenced trials with a leading Singapore hospital group, focusing on Hospital Acquired Infection control.

The Company has developed a new line of antimicrobial wellness products and within this category the Resoothe Wellness tape obtained TGA approval in Australia, in December 2022.

#### Indian Joint Venture:

During the half-year period the Company signed an agreement to distribution its products in India and have targeted key accounts and hospitals in India to market Nanoveu's products, particularly on its air filters line of products and surface protection.

## Directors' Report (continued)

### EyeFyx Project:

The Company diverted much of its technical resources into its Antiviral projects but continued development with its technology partner Nanyang Technology University (NTU) for its EyeFyx Project. Together with NTU, the Company intends to progress its current PCT patent filing into the USA.

### Successful Capital Raisings

In October 2022, Nanoveu raised \$475,000 (before costs) through a placement to sophisticated and professional investors at \$0.01 per share ("Shares"). This was the first tranche of a two stage placement.

Subsequent to year end, and following approval by shareholders, the second tranche of \$525,000 was raised from the issue of 52,500,000 shares at \$0.01 per share and 50,000,000 options with an exercise price of \$0.02 each on or before 26 January 2026.

62 Capital Pty Ltd acted as the lead manager and subsequent to year end were issued 6,000,000 shares and 3,000,000 options with an exercise price of \$0.02 on or before 26 January 2026.

### Repayment of Equity Facility:

Part of the proceeds from the capital raise have been and will be used to repay the amount outstanding to the investor under the funding agreement announced to the ASX on 14 August 2020, being \$626,000. \$326,000 of that amount was repaid by the Company on 4 November 2022, followed by five monthly instalments of \$60,000 each commencing in 2023.

Nanoveu issued 7,500,000 options with an exercise price of \$0.02 and 4 October 2025 expiry to the investor in consideration for the variation of the agreement to permit repayment of the amount outstanding.

### *Significant changes in the state of affairs*

There have been no significant changes in the state of affairs of the Company to the date of this report, not otherwise disclosed in this report.

### *Review of financial condition*

The Group reported a loss before tax from continuing operations of \$2,707,301 (2021: \$2,320,618) for the year ended 31 December 2022 an increase of 17% from the prior year.

### *Liquidity and capital resources*

The Group had \$248,142 (2021: \$2,013,375) cash at bank at 31 December 2022.

The consolidated cash flow statement illustrates that there was a decrease in cash and cash equivalents in the year ended 31 December 2022 of \$1,765,233 (2021: \$1,047,490) inclusive of cash used in operating activities of \$1,886,645 (2021: \$2,246,982).

### *Business strategies and prospects for future financial years*

The Company is deploying its anti-viral protection product for digital screen and flat surfaces via distributors. With distributors engaged in Australia, Malaysia, Singapore, Thailand and the United Kingdom, the Company is actively seeking to expand its distribution network while pursuing sales directly with customers with a global presence and retail customer base. Applications for the technology are being expanded, with the Company targeting the solar photo-voltaic sector to reduce the growth of surface material such as algae and lichen which is problematic in humid climates.

Development of the EyeFyx vision correction product for digital displays has been delayed due to the Company's focus on its range of antiviral products. However, the Company is preparing to continue development of EyeFyx during 2023. Upon solving all technical issues, the Company will target a review of manufacturing partners.. This is a complex project with multiple technical challenges and addresses a large market space so the Company will need to take its time to manage its limited resources to prioritize its focus on antiviral products against this greenfield market opportunity.

## Directors' Report (continued)

### Significant events after reporting date

Subsequent to year end, and following approval by shareholders, the Company completed the second tranche of a placement from which \$525,000 was raised from the issue of 52,500,000 shares at \$0.01 per share and 50,000,000 options with an exercise price of \$0.02 each on or before 26 January 2026.

62 Capital Pty Ltd acted as the lead manager and subsequent to year end were issued 6,000,000 shares and 3,000,000 options with an exercise price of \$0.02 on or before 26 January 2026.

Other than the matters noted above, there has not arisen in the interval between the end of the financial period and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the Directors of the Company, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group in future.

### Likely developments and expected results of operations

The Company expects to continue commercialisation of its anti-viral protection product for digital screens and flat surfaces, and complete the first stage of development of EyeFyx, its vision correction product for digital displays.

### Environmental legislation

The Company's operations are not regulated by any significant environmental regulations under a law of the Commonwealth or of a state or territory.

### Share options and performance rights

#### (a) Share options

*Options on issue:*

Unissued ordinary shares of the Company under option:

Terms of Options	Number on Issue at 31 Dec 2022	Number on Issue at 31 Dec 2021
Unlisted options with an exercise price of \$0.10 on or before 22 Dec 2022	-	3,300,000
Unlisted options with an exercise price of \$0.1018 on or before 28 Oct 2023	3,900,000	3,900,000
Unlisted options with an exercise price of \$0.058 on or before 6 Sep 2023	1,000,000	1,000,000
Unlisted options with an exercise price of \$0.058 on or before 5 Oct 2023	5,902,855	5,902,855
Unlisted options with an exercise price of \$0.058 on or before 1 Feb 2024	15,000,000	15,000,000
Unlisted options with an exercise price of \$0.02 on or before 4 October 2025	7,500,000	-
<b>Total at year end</b>	<b>33,302,855</b>	<b>29,102,855</b>
<b>Issued subsequent to year end</b>		
Unlisted options with an exercise price of \$0.02 on or before 26 January 2025	53,000,000	
<b>Total on issue at the date of this report</b>	<b>86,302,855</b>	

**Directors' Report (continued)****(b) Performance rights**

Tranche	Performance Hurdle	Opening	Granted	Expired	Converted	Closing
C	Completion of iPhone Series X production of at least 100,000 units	223,000	-	-	-	223,000
D	Completion of production of the first three Android models of at least 100,000 units	217,500	-	-	-	217,500
E	12 months from completion of gaming software development kit or launch of first five 3D games introduced to market	434,000	-	-	-	434,000
F	Securing distribution in China with sales of at least 100,000 units	610,000	-	-	-	610,000
K	A\$8m of sales revenue across all by 31 December 2022 as validated from audited / reviewed financial reports	2,710,000	-	(2,710,000)	-	-
L	A\$15m of sales revenue across all by 31 December 2023 as validated from audited / reviewed financial reports	2,260,000	-	-	-	2,260,000
M	The Company securing exclusive commercial and marketing rights of all antiviral products developed by Innox Limited by 31 December 2021 as validated by an exclusive licencing agreement	500,000	-	-	(500,000)	-
O	A\$2.7m of EyeFyx product sales revenue by 31 December 2022 as validated from audited / reviewed financial reports	250,000	-	(250,000)	-	-
P	A\$5m of EyeFyx product sales revenue by 31 December 2023 as validated from audited / reviewed financial reports	250,000	-	-	-	250,000
Total		7,454,500	-	(2,960,000)	(500,000)	3,994,500

**Indemnification and insurance of Directors and Officers**

The Company has agreed to indemnify all the directors and executive officers against all liabilities to another person (other than the Company or related body corporate) that may arise from their position as officers of the Company and its controlled entities, except where the liability arises out of conduct involving a lack of good faith. The agreement stipulates that the Company will meet the full amount of any such liabilities, including costs and expenses.

The Company has also agreed to indemnify the current Directors of its controlled entities for all liabilities to another person (other than the Company or related body corporate) that may arise from their position, except where the liability arises out of conduct involving a lack of good faith. The agreement stipulates that the Company will meet the full amount of any such liabilities, including costs and expenses.

## Directors' Report (continued)

### Auditor Independence and Non-Audit Services

The auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' Report.

Details of the amounts paid or payable to the auditors BDO Audit (WA) Pty Ltd for audit and interim review services provided during the year are set out below:

<b>Audit Services</b>	<b>2022</b>	<b>2021</b>
	<b>\$</b>	<b>\$</b>
BDO Audit (WA) Pty Ltd	33,000	33,000

### Non-Audit Services

There were no non-audit services provided during the 2022 year and the directors are of the opinion that the services as disclosed in Note 21 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the company, acting as advocate for the company or jointly sharing economic risks and rewards.

### Proceedings on Behalf of the Company


There are no proceedings on behalf of the Company under section 237 of the Corporations Act 2001 in the financial period or at the date of this report.

DECLARATION OF INDEPENDENCE BY JACKSON WHEELER TO THE DIRECTORS OF NANOVEU LIMITED

As lead auditor of Nanoveu Limited for the year ended 31 December 2022, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Nanoveu Limited and the entities it controlled during the period.



Jackson Wheeler  
Director

BDO Audit (WA) Pty Ltd  
Perth  
28 February 2023

For personal use only

## Directors' Report - Remuneration Report (audited)

This remuneration report for the financial year ended 31 December 2022 outlines remuneration arrangements of the Company in accordance with the requirements of the Corporations Act 2001 (the Act) and its regulations. This information has been audited as required by section 308(3C) of the Act.

The remuneration report details the remuneration arrangements for key management personnel (KMP) who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any director (whether executive or otherwise) of the parent company, and including the executives receiving the highest remuneration.

For the purposes of this report, the term "executive" includes the Chief Executive Officer (CEO), executive directors and senior management and the term "director" refers to non-executive directors only.

### Individual key management personnel disclosures

Details of KMPs of the Company are set out below:

#### *Key management personnel*

##### **Directors**

Mr Scott Beeton	Non-executive Chairman, appointed 22 September 2021, resigned 31 August 2022
Mr Alfred Chong	Managing Director and CEO, appointed 14 February 2018
Mr Michael van Uffelen	Director, CFO and Company Secretary, appointed 14 February 2018
Mr Steven Apedaile	Non-executive Director, appointed 14 May 2018
Mr David Nicol	Non-executive Director, appointed 17 July 2018, retired 2 March 2022

The Remuneration Report is set out under the following main headings:

- A. Principles used to determine the nature and amount of remuneration
- B. Details of remuneration
- C. Service agreements
- D. Share-based compensation
- E. Option holdings of key management personnel
- F. Performance Rights holdings of key management personnel
- G. Share holdings of key management personnel
- H. Other transactions and balances with key management personnel

### **A. Principles used to determine the nature and amount of remuneration**

#### *Remuneration philosophy*

The performance of the Group depends upon the quality of its directors and executives. To prosper, the Group must attract, motivate and retain highly skilled directors and executives.

To this end, the Group embodies the following principles in its compensation framework:

- Provide competitive rewards to attract high calibre executives;
- Link executive rewards to shareholder value; and
- Establish appropriate, demanding performance hurdles in relation to variable executive compensation

Remuneration consists of fixed remuneration and variable remuneration.

## Directors' Report - Remuneration Report (audited) (continued)

### *Fixed Remuneration*

Fixed remuneration is reviewed annually by the Board of Directors. The process consists of a review of relevant comparative remuneration in the market and internally and, where appropriate, external advice on policies and practices.

### *Variable Remuneration*

The Group currently has a discretionary variable component to the remuneration of the board and management and intends to introduce a structured variable remuneration plan in the near future.

### *Remuneration Reviews*

The Board of Directors of the Company is responsible for determining and reviewing compensation arrangements for the directors, the Managing Director and all other key management personnel.

The Board of Directors assesses the appropriateness of the nature and amount of compensation of key management personnel on a periodic basis by reference to relevant employment market conditions with the overall objective of ensuring maximum stakeholder benefit from the retention of a high-quality board and executive team.

### *Remuneration structure*

In accordance with best practice Corporate Governance, the structure of non-executive director and executive remuneration is separate and distinct.

### *Non-executive Director Remuneration*

The Board seeks to set aggregate remuneration at a level that provides the Group with the ability to attract and retain directors of the highest calibre, whilst incurring a cost that is acceptable to shareholders.

The Constitution specifies that the aggregate remuneration of non-executive directors shall be determined from time to time by a general meeting. The amount of aggregate remuneration sought to be approved by shareholders and the manner in which it is apportioned amongst directors is reviewed annually. The Board considers advice from external shareholders as well as the fees paid to non-executive directors of comparable companies when undertaking the annual review process.

Non-executive directors receive a fee for being a director of the Company. The compensation of non-executive directors for the year ended 31 December 2022 is detailed below.

The total maximum remuneration of non-executive directors is initially set by the Constitution and subsequent variation is by ordinary resolution of Shareholders in general meeting in accordance with the Constitution, and the Corporations Act, as applicable. The determination of non-executive directors' remuneration within that maximum will be made by the Board having regard to the inputs and value to the Company of the respective contributions of each non-executive Director. This amount has been set at an amount not to exceed \$300,000 per annum.

In addition, a director may be paid fees or other amounts and non-cash performance incentive such as options and performance rights, subject to necessary shareholder approval, where a director performs special duties or otherwise performs services outside the scope of the ordinary duties of a director.

Directors are also entitled to be reimbursed reasonable travelling, hotel and other expenses incurred by them respectively in or about the performance of their duties as directors.

### *Director Remuneration*

Remuneration of each director has been set at \$48,000 per annum plus superannuation of 9.5% which commenced being paid from admission to the Official List of the Australian Securities exchange. In addition, directors were offered performance rights for their services without cash remuneration prior to admission to the Official List of the Australian Securities exchange.

Remuneration for executive roles are separate and in addition to remuneration as a director. Accordingly, executive directors have a director contract and a separate contract for their executive services.

## Directors' Report - Remuneration Report (audited) (continued)

### Senior Manager and Executive Director remuneration

#### Objective

The entity aims to reward executives with a level and mix of compensation commensurate with their position and responsibilities within the entity so as to:

- reward executives for company, business unit and individual performance against targets set to appropriate benchmarks;
- align the interests of executives with those of shareholders;
- link rewards with the strategic goals and performance of the Company; and
- ensure total compensation is competitive by market standards.

Compensation consists of the following key elements:

- Fixed Compensation; and
- Variable Compensation.

The proportion of fixed compensation and variable compensation (potential short term and long term incentives) is established for each key management person by the Directors.

#### Fixed Compensation

##### Objective

Fixed compensation is reviewed annually by the Directors. The process consists of a review of individual performance, relevant comparative compensation in the market and internally and, where appropriate, external advice on policies and practices. This review is based on a calendar year cycle and is typically performed in December / January.

##### Structure

Executives are given the opportunity to receive their fixed remuneration in a variety of forms including cash and fringe benefits such as motor vehicles and expense payment plans.

#### Variable Compensation

##### Objective

The objective of the Variable Compensation is to reward executives in a manner that aligns this element of compensation with the creation of shareholder wealth.

##### Structure

The Group currently has a discretionary variable component to the remuneration of the board and management and intends to introduce a structured variable remuneration plan in the near future.

#### Use of remuneration consultants

The Group did not use the services of remuneration consultants.

#### Objective of the remuneration committee

The Group did not have a remuneration committee during the period.

#### Overview of Group performance

	2022	2021	2020	2019	2018
Net loss	\$(2,707,301)	\$(2,320,618)	\$(1,762,016)	\$(3,373,018)	\$(1,568,309)
Share price at year end	0.9 cents	3.2 cents	6.5 cents	5.2 cents	8.2 cents
Basic EPS (loss)	(1.2) cents	(1.2) cents	(1.3) cents	(2.5) cents	(1.6) cents

The Group currently has a discretionary variable component to the remuneration of the board and management and intends to introduce a structured variable remuneration plan in the future.

**Directors' Report - Remuneration Report (audited) (continued)****B. Details of remuneration***Year ended 31 December 2022*

	Salary, fees & commissions	Bonus	Non- monetary benefits (iv)	Post employ- ment benefits	Share- based payments (v)	Total	Portion of Remuner- ation Perform- ance Related
<b>Directors</b>							
<i>Executive</i>							
Mr Alfred Chong	184,380	-	9,365	11,880	(20,703)	188,792	-
Mr Michael van Uffelen (i)	146,567	-	7,040	3,870	(20,703)	136,774	-
<i>Non-executive</i>							
Mr Scott Beeton (ii)	29,600	-	1,524	2,960	-	34,084	-
Mr Steven Apedaile (iii)	40,800	-	2,100	4,080	(2,070)	44,910	-
Mr David Nicol (vi)	8,000	-	412	800	(2,070)	7,142	-
<b>Total Directors</b>	<b>409,347</b>	<b>-</b>	<b>20,441</b>	<b>27,460</b>	<b>(45,546)</b>	<b>411,702</b>	<b>-</b>
<b>Other KPMs</b>							
Nil	-	-	-	-	-	-	-
<b>Total Other KPMs</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total KPMs</b>	<b>409,347</b>	<b>-</b>	<b>20,441</b>	<b>27,460</b>	<b>(45,546)</b>	<b>411,702</b>	<b>-</b>

*Compensation is stated on an accruals basis.*

- (i) Includes remuneration via Black Tourmaline Consulting, a business in which he holds a beneficial interest.
- (ii) Includes remuneration via Springboard Financial Group Pty Ltd, a business in which he holds a beneficial interest. Resigned 31 August 2022
- (iii) Includes remuneration via Apedaile Nominees Pty Ltd, a business in which he holds a beneficial interest.
- (iv) Comprises of directors and officers insurance.
- (v) Share based payments comprise the amortisation of the measured cost of performance rights issued at grant date. This grant date cost is based on the price of the Company's shares which is amortised to the estimated date of the hurdle being achieved based on an assessment of the probability of achievement of the hurdles specified in the performance rights. The ultimate benefit received by the participant may be materially different to this calculated value, and may be received at a significantly different time to the date presented in this table. The negative value represents the reversal of higher amortisation in prior periods following a reassessment of the probability of performance rights vesting. As the hurdles are not expected to be achieved, this amount was set to nil in the current year.
- (vi) Retired 2 March 2022

**Directors' Report - Remuneration Report (audited) (continued)**

Year ended 31 December 2021

Directors	Salary, fees & commissions	Bonus	Non- monetary benefits (iv)	Post employ- ment benefits	Share- based payments (v)	Total	Portion of Remuner- ation Perform- ance Related
<i>Executive</i>							
Mr Alfred Chong	199,254	-	8,849	15,346	6,558	230,007	3%
Mr Michael van Uffelen (i)	158,350	-	6,720	4,600	13,558	183,228	7%
<i>Non-executive</i>							
Mr Scott Beeton (ii)	13,200	-	599	1,320	-	15,119	-
Mr Steven Apedaile (iii)	47,200	-	2,136	4,600	831	54,767	2%
Mr David Nicol	47,200	-	2,136	4,600	831	48,404	2%
<b>Total Directors</b>	<b>465,204</b>	<b>-</b>	<b>20,440</b>	<b>30,466</b>	<b>21,778</b>	<b>54,767</b>	<b>6%</b>
<b>Other KPMs</b>							
Nil	-	-	-	-	-	-	-
<b>Total Other KPMs</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total KMPs</b>	<b>465,204</b>	<b>-</b>	<b>20,440</b>	<b>30,466</b>	<b>(150,994)</b>	<b>365,116</b>	<b>-41%</b>

Compensation is stated on an accruals basis.

- (i) Includes remuneration via Black Tourmaline Consulting, a business in which he holds a beneficial interest.
- (ii) Includes remuneration via Springboard Financial Group Pty Ltd, a business in which he holds a beneficial interest.
- (iii) Includes remuneration via Apedaile Nominees Pty Ltd, a business in which he holds a beneficial interest.
- (iv) Comprises of directors and officers insurance.
- (v) Share based payments comprise the amortisation of the measured cost of performance rights issued at grant date. This grant date cost is based on the price of the Company's shares which is amortised to the estimated date of the hurdle being achieved based on an assessment of the probability of achievement of the hurdles specified in the performance rights. The ultimate benefit received by the participant may be materially different to this calculated value, and may be received at a significantly different time to the date presented in this table. The negative value represents the reversal of higher amortisation in prior periods following a reassessment of the probability of performance rights vesting.

**C. Service agreements***Agreements with Executives*Alfred Chong – Executive Chairman

The Company entered into an executive services agreement (Executive Services Agreement) with Mr Chong dated 15 May 2018, pursuant to which the Company has engaged Mr Chong as Chief Executive Officer. The material terms and conditions of the Executive Services Agreement are summarised below:

- (a) Term: The Executive Services Agreement commenced on 1 June 2018 and replaced an earlier agreement dated 1 February 2013 and continues until terminated in accordance with its terms.
- (b) Remuneration: Mr Chong will receive from the commencement of his appointment, a salary of approximately S\$150,000 per annum plus the Singaporean Central Provident Fund contribution and a travel allowance of S\$12,000 per annum.
- (c) Incentive Programs: In addition to the Performance Rights he will receive on completion of the Offer, Mr Chong may participate in any incentive plan that the Company may introduce from time to time.
- (d) Termination: The Company may immediately terminate the employment of Mr Chong by written notice for a number of standard events including, but not limited to, if at any time Mr Chong:
  - (i) commits a serious or repeated or continual breach of the obligations under the Executive Services Agreement;
  - (ii) is guilty of any serious misconduct or serious neglect or dishonesty in the discharge of his duties under the Executive Services Agreement; or

## Directors' Report - Remuneration Report (audited) (continued)

- (iii) acts in a manner which, in the reasonable opinion of the Company, brings the name or reputation of the Company or any member of the Company into serious disrepute or prejudices the interests of the business of the Company.

The Company or Mr Chong may terminate the Executive Services Agreement for any reason by giving 6 months' written notice.

The Executive Services Agreement contains other standard terms and conditions expected to be included in contracts of this nature.

### Michael van Uffelen – Director, CFO and Company Secretary

The Company entered into a consulting agreement (Consulting Agreement) with Black Tourmaline Pty Ltd ATF Black Tourmaline Consulting (Black Tourmaline Consulting), an entity controlled by Mr van Uffelen and in which he has a beneficial interest, pursuant to which the Company has engaged Mr van Uffelen to act as Chief Financial Officer and Company Secretary. The material terms and conditions of the Executive Services Agreement are summarised below:

- (a) Term: The Executive Services Agreement commenced on 1 May 2018 and continues until terminated in accordance with its terms.
- (b) Remuneration: Black Tourmaline Consulting will receive from 1 May 2018 a fee of \$6,000 per month, which was amended to \$9,500 per month during the 2020 year, plus GST.
- (c) Incentive Programs: Black Tourmaline Consulting may participate in any incentive plan that the Company may introduce from time to time.
- (d) Termination: The Company or Black Tourmaline Consulting may terminate the Consulting Agreement for any reason by giving 3 months' written notice.

The Consulting Agreement contains other standard terms and conditions expected to be included in contracts of this nature.

### *Agreements with all directors*

The Company has entered into agreements with all directors. The material terms of the agreement are as follows:

- (a) Director's fees: director's fees at the rate of \$48,000 per annum plus superannuation together with reimbursement for out of pocket expenses incurred as a result of engagement as a director.
- (b) Termination: Non-Executive Directors may retire at any time and are subject to re-election at the annual general meeting of shareholders in accordance with the Company's policy of at least one third of the Non-Executive Directors being nominated for re-election each year based on the Company's rotation schedule.

**Directors' Report - Remuneration Report (audited) (continued)****D. Share-based compensation***Compensation shares, options and performance rights granted to key management personnel*

Key management personnel did not receive any share-based compensation during the year.

*Performance rights of key management personnel*

The table below shows the number of Performance Rights granted, converted and forfeited during the year.

	Balance at start of year	Granted as remuneration	Converted	Forfeited	Balance at end of year	Maximum value yet to vest (\$) (i)
<b>Directors</b>						
Mr Scott Beeton	-	-	-	-	-	-
Mr Alfred Chong	2,150,000	-	-	(750,000)	1,400,000	129,250
Mr Michael van Uffelen	1,683,500	-	-	(750,000)	933,500	104,750
Mr Steven Apedaile	155,000	-	-	(75,000)	80,000	9,775
Mr David Nicol	155,000	-	-	(155,000)	-	-
<b>Total Directors</b>	<b>4,143,500</b>	-	-	<b>(1,730,000)</b>	<b>2,413,500</b>	<b>243,775</b>

(i) Calculated at grant date.

The vesting of Performance Rights is subject to the following performance hurdles:

Tranche	Performance Hurdle	Alfred Chong	Michael van Uffelen	Steven Apedaile
C	Completion of iPhone Series X production of at least 100,000 units	200,000	117,000	15,000
D	Completion of production of the first three Android models of at least 100,000 units	100,000	58,500	7,500
E	Remaining employed/engaged by the Company in June 2021 (this hurdle has been achieved, but the shares are yet to be issued)	100,000	58,000	7,500
F	Securing distribution in China with sales of at least 100,000 units	300,000	200,000	-
L	A\$15m of sales revenue across all by 31 December 2023 as validated from audited / reviewed financial reports	600,000	500,000	50,000
<b>Total</b>		<b>2,150,000</b>	<b>1,683,500</b>	<b>155,000</b>

The shares to be issued in the event of vesting of the Performance Rights shall rank pari-passu in all respects with other fully paid ordinary shares in the Company.

Key management personnel did not receive any share-based compensation during the year.

**Directors' Report - Remuneration Report (audited) (continued)****E. Option holdings of key management personnel**

	Balance at start of the financial period	Granted as remuneration	Exercised	Net change other	Balance at the end of financial period / ceasing service	Vested and exercisable
<b>Directors</b>						
Mr Scott Beeton	-	-	-	-	-	-
Mr Alfred Chong	250,000	-	-	-	250,000	250,000
Mr Michael van Uffelen	77,063	-	-	-	77,063	77,063
Mr Steven Apedaile	100,035	-	-	-	100,035	100,035
Mr David Nicol	72,250	-	-	-	72,250	72,250
<b>Total Directors</b>	<b>499,348</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>499,348</b>	<b>499,348</b>

Options are exercisable at \$0.058 each on or before 27 October 2023 and were acquired via participation in an entitlement issue in 2021.

**F. Share holdings of key management personnel**

<u>31 December 2022</u>	Balance at start of the period	On conversion of performance rights	Acquisitions	Disposals	Balance at the end of period / date of ceasing to be a KMP
<b>Directors</b>					
Mr Scott Beeton	-	-	-	-	-
Mr Alfred Chong	43,127,558	-	-	-	43,127,558
Mr Michael van Uffelen	770,625	-	-	-	770,625
Mr Steven Apedaile	1,000,350	-	-	-	1,000,350
Mr David Nicol	722,500	-	-	-	722,500
<b>Total Directors</b>	<b>45,621,033</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>45,621,033</b>

**G. Other transactions and balances with Key Management Personnel**

Apart from the above item and reimbursements for expenses paid on behalf of the Company, director and fees paid directly or indirectly to director related entities, there were no transactions or balances with KMP during the years ended 31 December 2022 and 2021.

**H. Voting and comments made at the Company's Annual General Meeting**

At the Annual General Meeting held on 31 May 2022, 99.3% of votes cast were in favour of the adoption of the Company's remuneration report for the 2021 financial year. The Company did not receive any comments at the Annual General Meeting on its remuneration report.

END OF THE AUDITED REMUNERATION REPORT

Signed in accordance with a resolution of the Directors:



**Alfred Chong**  
**Managing Director and CEO**  
 Singapore, 28<sup>th</sup> February 2023

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND  
OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	2022 \$	2021 \$
Revenue from contracts with customers	6	159,512	781,214
<b>Revenue</b>		<b>159,512</b>	<b>781,214</b>
Cost of sale of goods	11	(87,141)	(394,655)
<b>Gross profit (loss)</b>		<b>72,371</b>	<b>386,559</b>
Other operating income	6	23,043	66,955
Selling and distribution expenses	6	(476,677)	(680,409)
Administration expenses	6	(1,503,474)	(1,421,286)
Research costs	6	(9,536)	(230,704)
Share based payment expense	7	100,992	(77,836)
Impairment	6	(738,860)	(66,440)
<b>Operating profit (loss)</b>		<b>(2,532,141)</b>	<b>(2,023,161)</b>
Finance income	6	1,136	432
Finance costs	13	(176,296)	(297,889)
<b>(Loss) before income tax</b>		<b>(2,707,301)</b>	<b>(2,320,618)</b>
Income tax expense	8	-	-
<b>(Loss) for the year</b>		<b>(2,707,301)</b>	<b>(2,320,618)</b>
<b>Other comprehensive income / (loss)</b>			
<i>Items that may be reclassified to profit or loss:</i>			
- Foreign currency differences on translation of foreign operations		(54,820)	78,221
		(54,820)	78,221
<b>Total comprehensive (loss) for the year</b>		<b>(2,762,121)</b>	<b>(2,242,397)</b>
Loss per share – basic and diluted attributable to the members of Nanoveu Limited	5	(1.2)	(1.3)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

### AS AT 31 DECEMBER 2022

	Note	2022 \$	2021 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	9	248,142	2,013,375
Trade and other receivables	10	116,592	205,961
Inventories	11	-	469,298
<b>Total Current Assets</b>		<b>364,734</b>	<b>2,688,634</b>
<b>NON-CURRENT ASSETS</b>			
Plant and equipment		62,598	64,955
<b>Total Non-current Assets</b>		<b>62,598</b>	<b>64,955</b>
<b>TOTAL ASSETS</b>		<b>427,332</b>	<b>2,753,589</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables	12	379,775	161,409
Financial liability	13	300,000	986,682
Provisions		20,970	20,895
<b>Total Current Liabilities</b>		<b>700,745</b>	<b>1,168,986</b>
<b>TOTAL LIABILITIES</b>		<b>700,745</b>	<b>1,168,986</b>
<b>NET ASSETS / (DEFICIENCY)</b>		<b>(273,413)</b>	<b>1,584,603</b>
<b>EQUITY</b>			
Issued capital	14	17,737,687	16,769,439
Accumulated losses		(16,976,650)	(14,269,349)
Reserves		(1,034,450)	(915,487)
<b>TOTAL EQUITY</b>		<b>(273,413)</b>	<b>1,584,603</b>

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes

## CONSOLIDATED STATEMENT OF CASH FLOWS

### FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	2022 \$	2021 \$
<b>Cash flows from Operating Activities</b>			
Receipts from customers		159,512	715,543
Government grant received		23,043	66,955
Payments to suppliers and employees		(2,091,043)	(2,823,694)
Interest received		1,136	432
<b>Net cash (used in) operating activities</b>	9(b)	<b>(1,907,352)</b>	<b>(2,040,764)</b>
<b>Cash Flows from Financing Activities</b>			
Proceeds from the issuance of shares	14	475,000	2,042,258
Repayment of equity facility loan	13	(326,129)	-
Issue of convertible notes	13	-	1,000,000
Share issue expenses		(6,752)	(136,036)
<b>Net cash provided by financing activities</b>		<b>142,119</b>	<b>2,906,222</b>
Net increase (decrease) in cash held		(1,765,233)	865,458
Cash at the beginning of the financial year		2,013,375	1,147,917
<b>Cash at the end of the financial year</b>	9	<b>248,142</b>	<b>2,013,375</b>

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2022

	Issued Capital	Accumulated Losses	Option Reserve	Common Control Reserve	Share Based Payment Reserve	Foreign Currency Translation Reserve	Total
	\$	\$	\$	\$	\$	\$	\$
Balance at 1 January 2021	14,211,972	(11,948,731)	342,620	(1,710,087)	281,662	35,505	1,212,942
Loss for the year	-	(2,320,618)	-	-	-	78,221	(2,242,397)
Total comprehensive loss for the year	-	(2,320,618)	-	-	-	78,221	(2,242,397)
<i>Transactions with owners in their capacity as owners:</i>							
Shares issued	2,042,258	-	-	-	-	-	2,042,258
Vesting of performance rights	42,005	-	-	-	(42,005)	-	-
Share issue expenses	(156,796)	-	20,760	-	-	-	(136,037)
Equity facility conversion	630,000	-	-	-	-	-	630,000
Share based payments	-	-	-	-	77,836	-	77,836
<b>Balance at 31 December 2021</b>	<b>16,769,439</b>	<b>(14,269,349)</b>	<b>363,380</b>	<b>(1,710,087)</b>	<b>317,493</b>	<b>113,726</b>	<b>1,584,603</b>
Balance at 1 January 2022	16,769,439	(14,269,349)	363,380	(1,710,087)	317,493	113,726	1,584,603
Loss for the year	-	(2,707,301)	-	-	-	(54,820)	(2,762,121)
Total comprehensive loss for the year	-	(2,707,301)	-	-	-	(54,820)	(2,762,121)
<i>Transactions with owners in their capacity as owners:</i>							
Shares issued	475,000	-	-	-	-	-	475,000
Share issue expenses	(6,752)	-	-	-	-	-	(6,752)
Equity facility transaction costs	-	-	36,849	-	-	-	36,849
Equity facility conversion	500,000	-	-	-	-	-	500,000
Share based payments	-	-	-	-	(100,992)	-	(100,992)
<b>Balance at 31 December 2022</b>	<b>17,737,687</b>	<b>(16,976,650)</b>	<b>400,229</b>	<b>(1,710,087)</b>	<b>216,501</b>	<b>58,907</b>	<b>(273,413)</b>

The above Consolidated Statement of Statement of Changes in Equity should be read in conjunction with the accompanying notes

- (i) As a result of the capital reorganisation an equity account called 'Common Control Reserve' exists. This equity account represents the carrying value of the net liabilities of Nanoveu Limited prior to the date of completion of the capital reorganisation.

## Notes to the Financial Statements

### 1. CORPORATE INFORMATION

The consolidated financial statements of Nanoveu Limited and its subsidiaries (collectively, the Group) for the year ended 31 December 2022 were authorised for issue in accordance with a resolution of the directors on 28 February 2023. Nanoveu Limited (the Company or the parent) is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.

The principal activity of the Company was the deployment of nanotechnology for consumer applications.

### 2. SIGNIFICANT ACCOUNTING POLICIES

#### 2.1 Basis of preparation of the financial report

This general purpose financial report has been prepared in accordance with Australian Accounting Standards (AASBs) (including Australian Interpretations) adopted by the Australian Accounting Standards Board (AASB) and the Corporations Act 2001. Nanoveu Limited is a for profit entity for the purposes of preparing the financial statements.

#### 2.2 Basis of Measurement and Reporting Conventions Including Capital Reorganisation

The financial statements, except for cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded off to the nearest dollar unless stated otherwise.

On 14 February 2018, the Company was formed by major shareholders of Nanoveu Pte Ltd to list the Nanoveu business on the Australian Securities Exchange. As a result, the Company issued 90,584,250 shares to existing shareholders of Nanoveu Pte Ltd in exchange for all shares in Nanoveu Pte Ltd. There were no major changes to the shareholder group and the transaction does not result in any change in economic substance. Furthermore, the transaction is outside the scope of AASB3 Business Combinations since the Company does not meet the definition of a “business” as required by that standard. Accordingly, the consolidated financial statements of the Company are a continuation of Nanoveu Pte Ltd including comparative information being that of Nanoveu Pte Ltd.

#### *Common Control Entity*

On 16 November 2018, the Company completed a transaction with the shareholders of Nanoveu Pte Ltd (Singapore) under common control to acquire 100% of the share capital in Nanoveu Pte Ltd in exchange for 90,584,250 ordinary shares in the Company.

The financial report complies with Australian Accounting Standards, which include Australian equivalents to International Financial Reporting Standards (AIFRS). Compliance with AIFRS ensures that the financial report, comprising the financial statements and notes thereto, complies with International Financial Reporting Standards (IFRS).

#### 2.3 Going concern

The financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the ordinary course of business. The Group incurred a loss for the year ended 31 December 2022 of \$2,707,301 (2021: \$2,320,618) and net cash outflows from operating activities of \$1,886,645 (2021: \$2,040,764).

The ability of the Group to continue as a going concern is dependent on securing additional funding through either equity, debt or receipts, or a combination of all, to continue to fund its operational and technology development activities. These conditions indicate a material uncertainty that may cast a significant doubt about the Group’s ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The Directors believe that there are sufficient funds available to continue to meet the Group’s working capital requirements as at the date of this report and that sufficient funds will be available to finance the operations of the Group for the following reasons:

## Notes to the Financial Statements (continued)

The Directors of Nanoveu Limited have assessed the likely cash flow for the 12 month period from date of signing this financial report and its impact on the Group and believe there will be sufficient funds to meet the Group's working capital requirements as at the date of this report, based on the belief that additional funds will be received via product sales to finance the Company's activity and from raising additional capital.

The Group has historically demonstrated its ability to raise funds to satisfy its immediate cash requirements. Management have considered the future capital requirements of the Group and will consider all funding options as required. In January 2023, the Group raised \$525,000 from the issue of shares (see Note 21 for details).

The Directors of Nanoveu Limited have reason to believe that in addition to the cash flow currently available, additional funds from receipts are expected from the commercialisation of the Group's products.

Should the Group not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements or raise additional capital through equity or debts raisings and that the interim financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern and meet its debts as and when they become due and payable.

### 2.4 Basis of Consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries as at 31 December 2022. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee; and
- The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption, and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements; and
- The Group's voting rights and potential voting rights.

The group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary.

Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equityholders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it derecognises the related assets (including goodwill), liabilities, non-controlling interest and other components of equity while any resultant gain or loss is recognised in profit or loss. Any investment retained is recognised at fair value.

## Notes to the Financial Statements (continued)

### 2.5 Summary of Significant Accounting Policies

#### (a) Current versus non-current classification

The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is:

- Expected to be realised or intended to be sold or consumed in the normal operating cycle;
- Held primarily for the purpose of trading;
- Expected to be realised within twelve months after the reporting period; or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in the normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Group classifies all other liabilities as non-current.

#### (b) Fair value of assets and liabilities

The Group measures some of its assets and liabilities at fair value on either a recurring or non-recurring basis, depending on the requirements of the applicable Accounting Standard.

Fair value is the price the Group would receive to sell an asset or would have to pay to transfer a liability in an orderly (ie unforced) transaction between independent, knowledgeable and willing market participants at the measurement date.

As fair value is a market-based measure, the closest equivalent observable market pricing information is used to determine fair value. Adjustments to market values may be made having regard to the characteristics of the specific asset or liability. The fair values of assets and liabilities that are not traded in an active market are determined using one or more valuation techniques.

These valuation techniques maximise, to the extent possible, the use of observable market data.

To the extent possible, market information is extracted from either the principal market for the asset or liability (i.e. the market with the greatest volume and level of activity for the asset or liability) or, in the absence of such a market, the most advantageous market available to the entity at the end of the reporting period (i.e. the market that maximises the receipts from the sale of the asset or minimises the payments made to transfer the liability, after taking into account transaction costs and transport costs).

For non-financial assets, the fair value measurement also takes into account a market participant's ability to use the asset in its highest and best use or to sell it to another market participant that would use the asset in its highest and best use.

The fair value of liabilities and the entity's own equity instruments (excluding those related to share-based payment arrangements) may be valued, where there is no observable market price in relation to the transfer of such financial instruments, by reference to observable market information where such instruments are held as assets. Where this information is not available, other valuation techniques are adopted and, where significant, are detailed in the respective note to the financial statements.

#### *Valuation techniques*

In the absence of an active market for an identical asset or liability, the Group selects and uses one or more valuation techniques to measure the fair value of the asset or liability. The Group selects a valuation technique that is appropriate in the circumstances and for which sufficient data is available to measure fair value. The availability of sufficient and relevant data primarily depends on the specific characteristics of the asset or liability being measured. The valuation techniques selected by the Group are consistent with one or more of the following valuation approaches:

## Notes to the Financial Statements (continued)

- Market approach: valuation techniques that use prices and other relevant information generated by market transactions for identical or similar assets or liabilities;
- Income approach: valuation techniques that convert estimated future cash flows or income and expenses into a single discounted present value; or
- Cost approach: valuation techniques that reflect the current replacement cost of an asset at its current service capacity.

Each valuation technique requires inputs that reflect the assumptions that buyers and sellers would use when pricing the asset or liability, including assumptions about risks. When selecting a valuation technique, the Group gives priority to those techniques that maximise the use of observable inputs and minimise the use of unobservable inputs. Inputs that are developed using market data (such as publicly available information on actual transactions) and reflect the assumptions that buyers and sellers would generally use when pricing the asset or liability are considered observable, whereas inputs for which market data is not available and therefore are developed using the best information available about such assumptions are considered unobservable.

### *Fair value hierarchy*

Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

AASB 13 requires the disclosure of fair value information by level of the fair value hierarchy, which categorises fair value measurements into one of three possible levels based on the lowest level that an input that is significant to the measurement can be categorised into as follows:

#### *Level 1*

Measurements based on quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

#### *Level 2*

Measurements based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

#### *Level 3*

Measurements based on unobservable inputs for the asset or liability.

The fair values of assets and liabilities that are not traded in an active market are determined using one or more valuation techniques. These valuation techniques maximise, to the extent possible, the use of observable market data. If all significant inputs required to measure fair value are observable, the asset or liability is included in Level 2. If one or more significant inputs are not based on observable market data, the asset or liability is included in Level 3.

The Group would change the categorisation within the fair value hierarchy only in the following circumstances:

- if a market that was previously considered active (Level 1) became inactive (Level 2 or Level 3) or vice versa; or
- if significant inputs that were previously unobservable (Level 3) became observable (Level 2) or vice versa.

When a change in the categorisation occurs, the Group recognises transfers between levels of the fair value hierarchy (i.e. transfers into and out of each level of the fair value hierarchy) on the date the event or change in circumstances occurred.

### **(c) Revenue recognition**

Revenue is recognised on the sale of products. Revenue recognised is subject to the reversal constraint and is only recognised to the extent that it is highly probably of not reversing. The Group has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements, has pricing latitude, and is also exposed to inventory and credit risks.

## Notes to the Financial Statements (continued)

The specific recognition criteria described below must also be met before revenue is recognised.

### *Sale of goods*

When recognising revenue from the sale of goods to customers is recognised when control of the goods has passed to the customer, which is considered to be the point of delivery of the goods to the customer, as this is deemed to be the time that the customer obtains the benefit of the goods.

### *Interest income*

Interest income is recognised on a time proportionate basis that takes into account the effective yield on the financial asset.

### **(d) Government grants**

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed.

When the Group receives grants of non-monetary assets, the asset and the grant are recorded at nominal amounts and released to profit or loss over the expected useful life of the asset, based on the pattern of consumption of the benefits of the underlying asset by equal annual instalments.

### **(e) Income tax**

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by reporting date.

Deferred income tax is provided on all temporary differences at reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognised for all taxable temporary differences except:

- when the deferred income tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or
- when the taxable temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, and the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilised, except:

- when the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or
- when the deductible temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, in which case a deferred tax asset is only recognised to the extent that it is probable that the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilised.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

Unrecognised deferred income tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

## Notes to the Financial Statements (continued)

Income taxes relating to items recognised directly in equity are recognised in equity and not in profit or loss.

Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to the same taxable entity and the same taxation authority.

### (f) Other taxes

Revenues, expenses and assets are recognised net of the amount of Goods and Services Tax ('GST') except:

- when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables, which are stated with the amount of GST included.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the Statement of Financial Position.

Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority are classified as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority.

### (g) Foreign currency translation

The financial report is presented in Australian dollars, which is the Group's presentation and functional currency. The functional currencies of the subsidiaries are United States dollars and Singapore Dollars. Transactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date.

#### *Transactions and balances*

Transactions in foreign currencies are initially recorded by the Group's entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Differences arising on settlement or translation of monetary items are recognised in profit or loss with the exception of monetary items that are designated as part of the hedge of the Group's net investment in a foreign operation. These are recognised in other comprehensive income (OCI) until the net investment is disposed of, at which time, the cumulative amount is reclassified to profit or loss. Tax charges and credits attributable to exchange differences on those monetary items are also recorded in OCI.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.

The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or profit or loss are also recognised in OCI or profit or loss, respectively).

#### *Group companies*

On consolidation, the assets and liabilities of foreign operations are translated into Australian dollars at the rate of exchange prevailing at the reporting date and their statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions. The exchange differences arising on translation for consolidation are recognised in OCI. On disposal of a foreign operation, the component of OCI relating to that particular foreign operation is reclassified to profit or loss.

## Notes to the Financial Statements (continued)

Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising on the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.

### (h) Cash and cash equivalents

Cash comprises cash at bank and in hand. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

### (i) Trade and other receivables

Trade receivables are amounts due from customers for products sold in the ordinary course of business. Trade receivables are measured at the amount of consideration that is unconditional. The Group holds trade receivables with the objective to collect the contractual cash flows and measures them at amortised cost.

The Group will apply the simplified impairment methodology permitted by AASB 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

### (j) Inventories

Inventories are valued at the lower of cost and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for, as follows:

- Raw materials: purchase cost on a first-in/first-out basis; and
- Finished goods and work in progress: cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.

Net realisable value is the estimated selling price in the ordinary course

### (k) Plant and equipment

Plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:

- Office equipment 3 years
- Plant, machinery and equipment 3 years
- Furniture and fittings 3 years
- Computers 3 years

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit or loss when the asset is de-recognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

### (l) Intangible assets

#### *Research and development costs*

Research costs are expensed as incurred. An intangible asset arising from development expenditure on an internal project is recognised only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. Following the initial recognition of the development expenditure, the cost model is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses. Any expenditure so capitalised is amortised over the period of expected benefit from the related project.

## Notes to the Financial Statements (continued)

### (m) Trade and other payables

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to the Group prior to the end of the period that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services.

### (n) Loans and borrowings

All loans and borrowings are initially recognised at the fair value of the consideration received less directly attributable transaction costs. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the liabilities are de-recognised.

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

#### *Convertible notes*

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost or fair value. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a prepayment for liquidity services and amortised over the period of the facility to which it relates.

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period to get ready for their intended use or sale. Borrowing costs cease to be capitalised upon the earlier of extinguishment of the liability or the commencement of commercial production from the qualifying asset.

Borrowings are removed from the statement of financial position when the obligation specified in the contract is discharged, cancelled or expired. Where the terms of a financial liability are renegotiated and the entity issues equity instruments to a creditor to extinguish all or part of the liability (debt for equity swap), a gain or loss is recognised in profit or loss, which is measured as the difference between the carrying amount of the financial liability and the fair value of the equity instruments issued.

Borrowings are classified as current liabilities unless the group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.

### (o) Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

### (p) Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

When the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit or loss and other comprehensive income net of any reimbursement.

## Notes to the Financial Statements (continued)

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects the risks specific to the liability.

When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

### *Employee Benefits*

Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating long service leave are recognised in other payables in respect of employees' services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled. Liabilities for non-accumulating sick leave are recognised when the leave is taken and are measured at the rates paid or payable.

#### **(q) Share-based payment transactions**

The Group provides benefits to employees (including senior executives) and consultants of the Group in the form of share-based payments, whereby employees and consultants render services in exchange for shares or rights over shares (equity-settled transactions).

The cost of these equity-settled transactions with employees and consultants are measured by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by an internal valuation using an option pricing model.

In valuing equity-settled transactions, no account is taken of any performance conditions, other than conditions linked to the price of the shares of the Company (market conditions) if applicable.

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the vesting period).

The cumulative expense recognised for equity-settled transactions at each reporting date until vesting date reflects (i) the extent to which the vesting period has expired and (ii) the Group's best estimate of the number of equity instruments that will ultimately vest. No adjustment is made for the likelihood of market performance conditions being met as the effect of these conditions is included in the determination of fair value at grant date. The statement of profit or loss and other comprehensive income charge or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of that period.

No expense is recognised for awards that do not ultimately vest, except for awards where vesting is only conditional upon a market condition. If the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any modification that increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee, as measured at the date of modification.

If an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled and new award are treated as if they were a modification of the original award, as described in the previous paragraph.

#### **(r) Leases**

All leases are accounted for by recognising a right-of-use asset and a lease liability except for:

- Leases of low value assets; and
- Leases with duration of twelve months or less.

Lease liabilities are measured at the present value of the contractual payments due to the lessor over the lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is typically the case) this is not readily determinable, in which case the Group's incremental borrowing rate on commencement of the lease is used. Variable lease payments are only included in the measurement of the lease liability if they depend on an index or rate. In such cases, the initial measurement of the lease liability assumes the variable element will remain unchanged throughout the lease term. Other variable lease payments are expensed in the period to which they relate.

On initial recognition, the carrying value of the lease liability also includes:

Annual Financial Report for the year ended 31 December 2022

## Notes to the Financial Statements (continued)

- Amounts expected to be payable under any residual value guarantee;
- The exercise price of any purchase option granted in favour of the Group if it is reasonably certain to assess that option; and
- Any penalties payable for terminating the lease, if the term of the lease has been estimated on the basis of termination option being exercised.

Right-of-use assets are initially measured at the amount of the lease liability, reduced for any lease incentives received, and increased for:

- Lease payments made at or before commencement of the lease;
- Initial direct costs incurred; and
- The amount of any provision recognised where the Group is contractually required to dismantle, remove or restore the leased asset.

Subsequent to initial measurement lease liabilities increase as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. Right-of-use assets are amortised on a straight-line basis over the remaining term of the lease or over the remaining economic life of the asset if, rarely, this is judged to be shorter than the lease term.

When the Group revises its estimate of the term of any lease (because, for example, it re-assesses the probability of a lessee extension or termination option being exercised), it adjusts the carrying amount of the lease liability to reflect the payments to make over the revised term, which are discounted at the same discount rate that applied on lease commencement. The carrying value of lease liabilities is similarly revised when the variable element of future lease payments dependent on a rate or index is revised. In both cases an equivalent adjustment is made to the carrying value of the right-of-use asset, with the revised carrying amount being amortised over the remaining (revised) lease term.

### (s) Issued capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

### (t) Earnings per share

#### *Basic earnings per share*

Basic earnings per share are calculated by dividing the profit attributable to the owners of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

#### *Diluted earnings per share*

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

### (u) Segment Reporting

The Group predominantly deploys nanotechnology applications for consumer devices. For management purposes, the Company is organised geographically into two operating segments being the Americas and the Rest of the World, plus Head Office. All of the Company's activities are inter-related and discrete financial information is reported to the Board (Chief Operating Decision Maker) as a single segment.

## 2.6 Changes in Accounting Policies and Disclosures

### New, revised or amending Accounting Standards and Interpretations adopted

The Group has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

## Notes to the Financial Statements (continued)

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Group.

### New standards and interpretations not yet adopted

There are no standards that are not yet effective that would be expected to have a material impact on the Group in the current or future reporting periods and on future transactions.

### 3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

The application of accounting policies requires the use of judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

#### *Share-based payment transactions:*

The Group measures the cost of equity-settled share-based payments which are performance shares at fair value at the grant date.

The Group measures the cost of equity-settled share-based payments which are options at fair value at the grant date using an option pricing model, taking into account the terms and conditions upon which the instruments were granted. The fair value is determined by a valuation using a Black Scholes Option Pricing Model, using the assumptions detailed in Note 14.

The Group issued option, performance rights and performance options during the year ended 31 December 2022 based on the conditions set out in Note 14. The Group follows the guidelines of AASB 2 'Share Based Payments' and takes into account non-market vesting conditions and estimates the probability and expected timing of achieving the vesting conditions. For Full terms of the securities issued see Note 14.

### 4. SEGMENT REPORTING

The Group predominantly deploys nanotechnology applications for consumer devices. For management purposes, the Group is organised into business units based on its services and has three reportable segments, as follows:

- Americas;
- rest of the world; and
- corporate and head office.

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the consolidated financial statements.

Also, the Group's financing (including finance costs and finance income) and income taxes are managed on a Group basis and are not allocated to operating segments.

Transfer prices between operating segments are on an arm's length basis in a manner similar to transactions with third parties.

## Notes to the Financial Statements (continued)

Year Ended 31 December 2022	Americas	Rest of the World	Corporate and Head Office	Total Segments	Adjustments and Eliminations	Consolidated
<b>Revenue</b>						
External customers	907	158,605	-	159,512	-	159,512
Inter-segment	-	-	-	-	-	-
Total revenue (i)	907	158,605	-	159,512	-	159,512
<b>Income/(expenses)</b>						
Depreciation and amortisation	-	(45,016)	-	(45,016)	-	(45,016)
Segment profit/(loss)	(6,152)	(1,461,463)	(561,577)	(2,029,172)	(678,129)	(2,707,301)
Total assets	753	1,049,492	69,304	1,119,550	(692,218)	427,332
Total liabilities	(6,584)	(353,720)	(418,974)	(779,278)	78,533	(700,745)

Year Ended 31 December 2021	Americas	Rest of the World	Corporate and Head Office	Total Segments	Adjustments and Eliminations	Consolidated
<b>Revenue</b>						
External customers	882	780,332	-	781,214	-	781,214
Inter-segment	-	-	-	-	-	-
Total revenue (i)	882	780,332	-	781,214	-	781,214
<b>Income/(expenses)</b>						
Depreciation and amortisation	-	(50,439)	-	(50,439)	-	(50,439)
Segment profit/(loss)	(58,236)	(2,262,814)	432	(2,320,618)	(1)	(2,320,618)
Total assets	442	942,337	1,810,851	2,753,630	(41)	2,753,589
Total liabilities	(6,147)	(125,362)	(1,037,476)	(1,168,985)	-	(1,168,985)

Inter-segment revenues are eliminated upon consolidation and reflected in the 'adjustments and eliminations' column. All other adjustments and eliminations are part of detailed reconciliations presented further below.

### Adjustments and eliminations

Finance income and costs, and fair value gains and losses on financial assets are not allocated to individual segments as the underlying instruments are managed on a group basis. Current taxes and certain financial assets and liabilities are not allocated to those segments as they are also managed on a group basis. Inter-segment revenues are eliminated on consolidation.

(i) Revenue is recognised at a point in time.

### 5. LOSS PER SHARE

	2022	2021
	\$	\$
Basic and diluted loss per share (cents per share)	(1.2)	(1.2)

The loss and weighted average number of ordinary shares used in the calculation of basic earnings per share is as follows:

Loss for the year	(2,707,301)	(2,320,618)
Weighted average number of shares outstanding during the year used in the calculations of basic loss per share:	230,337,848	173,506,505

There is no dilution of shares due to options as the potential ordinary shares are not dilutive and are therefore not included in the calculation of diluted loss per share.

## Notes to the Financial Statements (continued)

### 6. RESULT FOR THE PERIOD

	2022	2021
	\$	\$
<b>Revenue from contracts with customers</b>		
Sale of goods	159,512	781,214
	<u>159,512</u>	<u>781,214</u>
<b>Other operating income</b>		
Government grant	23,043	66,955
	<u>23,043</u>	<u>66,955</u>
<b>Selling and distribution expenses</b>		
Advertising and marketing	207,033	151,706
Employee expenses	269,644	526,707
Website	-	1,996
	<u>476,677</u>	<u>680,409</u>
<b>Administration expenses</b>		
Audit fees	41,849	37,314
Consulting fees	921	114,724
Depreciation and amortisation	45,016	50,439
Director and employee expenses	894,469	579,145
Investor relations	-	138,500
Legal fees	82,876	65,892
Licence fees	-	69,319
Office rental	73,417	49,794
Sundry expenses	365,848	316,159
	<u>1,503,474</u>	<u>1,421,286</u>
<b>Research costs</b>		
Research costs (a)	9,536	106,710
Employee expenses	-	123,994
	<u>9,536</u>	<u>230,704</u>

(a) Research costs relate mainly to the EyeFyx project being conducted in collaboration with Singapore's National Technical University.

### Impairment

Inventory	586,119	-
Other assets – investment in a joint arrangement	152,741	66,440
	<u>738,860</u>	<u>66,440</u>

### Finance income

Interest income	1,136	432
	<u>1,136</u>	<u>432</u>

### 7. SHARE BASED PAYMENTS

During the year nil (2021: 8,930,000) Performance Rights were issued for nil cash consideration, including nil (2021: 4,700,000) Performance Rights issued to Key Management Personnel.

The probability of the performance hurdles being achieved was set at nil and accordingly a credit of \$100,922 was recognised in the income statement to reverse expense recognition in prior years.

Refer to Note 14 for further information.

## Notes to the Financial Statements (continued)

### 8. INCOME TAX

#### (a) Income tax recognised in profit/loss

No income tax is payable by the Company as it recorded a loss for income tax purposes for the period.

#### (b) Numerical reconciliation between income tax expense and the loss before income tax.

The prima facie income tax expense on pre-tax accounting loss from operations reconciles to the income tax expense in the financial statements as follows:

	2022	2021
	\$	\$
Accounting loss before tax	(2,707,301)	(2,320,618)
Income tax benefit at 25% (i)	544,785	580,154
Unrecognised tax losses	(544,785)	(580,154)
Income tax expense	-	-
<b>(c) Unrecognised deferred tax balances</b>		
Tax losses @ 25% (i)	(12,029,815)	(12,666,420)
Other	(44,340)	(9,199)
Net unrecognised deferred tax (asset) / liability at 25% (i)	(12,074,155)	(12,675,619)

A deferred tax asset attributable to income tax losses has not been recognised at balance date as the probability criteria disclosed in Note 2.5(e) is not satisfied and such benefit will only be available if the conditions of deductibility also disclosed in Note 2.5(e) are satisfied.

(i) Reflects the tax rate of the Company. The corporate tax rate in Singapore is 17% and in the United States is 28%.

### 9. CASH AND CASH EQUIVALENTS

	2022	2021
	\$	\$
Cash at bank	248,142	2,013,375
	248,142	2,013,375

Cash at bank earns interest at floating rates based on daily bank deposit rates.

#### (a) Reconciliation to the Statement of Cash Flows

For the purposes of the statement of cash flows, cash and cash equivalents comprise cash on hand and at bank.

Cash and cash equivalents as shown in the statement of cash flows are reconciled to the related items in the balance sheet as follows:

	2022	2021
	\$	\$
Cash and cash equivalents	248,142	2,013,375

## Notes to the Financial Statements (continued)

### (b) Reconciliation of loss after income tax to net cash flows from operating activities:

	2022	2021
	\$	\$
Loss for the year	(2,707,301)	(2,320,618)
Non cash flow items in loss for the year:		
- Depreciation and amortisation	45,016	50,439
- Non-cash finance costs (see Note 13)	176,296	297,889
- Share based payment	(100,992)	(77,836)
- Impairment	738,860	66,440
- Foreign currency difference	(97,479)	7,320
Changes in operating assets and liabilities:		
- (Increase) / decrease in other assets	(649,491)	(44,887)
- (Increase) in inventory	469,298	(91,846)
- (Decrease) / increase in trade and other payables	218,366	(69,913)
- Increase in provisions	75	6,214
Cash flow used in operating activities	<u>(1,907,352)</u>	<u>(2,040,764)</u>

### 10. TRADE AND OTHER RECEIVABLES

	2022	2021
	\$	\$
<b>Current:</b>		
Trade receivables	23,831	65,671
Prepayments	11,790	25,199
Other	80,971	115,091
	<u>116,592</u>	<u>205,961</u>

### 11. INVENTORIES

	2022	2021
	\$	\$
<b>Current:</b>		
Trading goods	3,877	3,684
Work in progress	582,242	465,614
Provision for inventory obsolescence	(586,119)	-
	<u>-</u>	<u>469,298</u>
Inventories recognised as an expense in cost of sales	<u>87,141</u>	<u>394,655</u>
	<u>87,141</u>	<u>394,655</u>

Due to the low level of sales in the current year, inventory was impaired.

## Notes to the Financial Statements (continued)

### 12. TRADE AND OTHER PAYABLES

	2022	2021
	\$	\$
<b>Current:</b>		
Trade payables	117,784	110,859
Accrued expenses	255,878	44,402
Other current liabilities	6,113	6,148
	<u>379,775</u>	<u>161,409</u>

### 13. FINANCIAL LIABILITIES

	2022	2021
	\$	\$
<b>Original Facility:</b>		
Opening balance	986,682	318,792
Funds advanced	-	1,000,000
Finance costs	127,724	295,869
Value of shares issued (see Note 14)	(500,000)	(630,000)
Closing balance	<u>616,428</u>	<u>986,682</u>
<b>Amended Facility:</b>		
Recognise financial liability	626,000	-
At Cash payment made	(326,000)	-
Closing balance	<u>300,000</u>	-
<b>Finance Costs Recognised:</b>		
Finance costs on initial facility	127,724	295,869
Finance cost for modification	48,572	-
	<u>176,296</u>	<u>295,869</u>

The Company secured a funding facility of up to \$2.4 million from Antiviral Technologies Portfolio LLC (“the Investor”) for subscriptions for ordinary shares of the Company as follows:

- A \$1,600,000 subscription for shares with the value of \$1,756,000 has been received by the Company.
- An additional \$800,000 subscription for shares with the value of \$878,000 may be made by mutual consent of the parties, subject to the Company obtaining shareholder approval for that subscription.

Each of these investments will be made by way of the Investor prepaying for shares which will be issued upon the Investor’s written request, within 18 months of the final subscription, in the number determined by applying to the subscription amount prepaid for by the Investor the “Purchase Price”, being the average of the five daily volume-weighted average prices (rounded down to the next one tenth of a cent, or if the share price exceeds \$0.10, the next half a cent) selected by the Investor at its discretion during the 20 consecutive actual trading days immediately prior to the Investor’s written request. Each issue must be for no less than \$150,000 of the shares.

The Company has made an initial issuance of 3,500,000 shares to the Investor for no consideration (“Collateral Shares”); the remainder of shares will be issued as set out above. Alternatively, in lieu of applying these shares towards the aggregate number of the Placement Shares to be issued by Nanoveu, the Investor may, at a date determined by the Investor (no later than five business days after the later of the date of termination of the Agreement or the date by which all of the investments under the Agreement have been made, and all of the shares issuable under the Agreement have been issued), elect to make a further payment to the Company equal

## Notes to the Financial Statements (continued)

to the value of these shares determined using the Purchase Price at the time of the payment. The Collateral Shares are reported as Treasury Shares until applied towards the Placement Shares or when consideration is received from the Investor.

The Company has:

- paid a fee to the Investor of \$100,000 (equivalent to 4.2% of the maximum placement amount), satisfied by way of an issuance of 1,587,302 Shares to the Investor which had a fair value of \$130,158 on issue date; and
- granted to the Investor 3,900,000 unlisted options to acquire ordinary shares at \$0.1018 each on or before 36-month anniversary of their grant date. This exercise price is at a 40% premium to the average of the daily VWAPs for Shares for the 20 consecutive actual trading days immediately prior to the date of the Agreement. These options had a fair value of \$196,156 and have been valued using a Black-Scholes methodology.

The difference between the amount received by the Company and the value of shares to be issued plus the fair value of the shares issued in lieu of fees and the fair value of the options granted to the Investor are amortised as notional interest over the term of each tranche of 18 months.

As shares are issued to settle the liability for shares, the liability is reduced by the value of the shares issued.

During the year, the Company and the provider of the facility agreed to amend the terms to allow repayment of the facility. \$326,000 was repaid by the Company by 4 November 2022, followed by five monthly instalments of \$60,000 each. At year end, \$300,000 was repayable. Previously the facility was valued at amortised cost.

Nanoveu issued 7,500,000 options with an exercise price of \$0.02 and a 3 year term to the investor in consideration of a variation of the agreement to permit an early repayment of the amount outstanding.

During the year, the Company recognised a total of \$176,296 in accrued finance costs through profit and loss, inclusive of the value of options issued to enable early repayment of the facility.

### 14. ISSUED CAPITAL

	2022	2021
	\$	\$
Paid up capital – ordinary shares	19,011,520	18,036,520
Capital raising costs	(1,273,833)	(1,267,081)
	<u>17,737,687</u>	<u>16,769,439</u>

#### (a) Ordinary shares

	Date	Number of shares	\$
<b>31 December 2022 movements in issued capital:</b>			
Balance at 1 January 2022		209,071,140	16,769,439
Placement at \$0.01 per share (i)	14 Oct 2022	47,500,000	475,000
Shares issued under an equity agreement (see Note 13)			
- Shares issued under the equity facility, at \$0.03 per share	11 Jan 2022	6,666,667	200,000
- Shares issued under the equity facility, at \$0.02 per share	5 May 2022	6,818,182	150,000
- Shares issued under the equity facility, at \$0.02 per share	22 Jul 2022	10,714,286	150,000
		<u>280,770,275</u>	<u>17,744,439</u>
Share issue expenses		-	(6,752)
Balance at 31 December 2022		<u>280,770,275</u>	<u>17,737,687</u>

- (i) Each 2 participating shares entitled the participant to 1 option with an exercise price of \$0.02 with a 3 year term, subject to shareholder approval which was obtained on 15 December 2022. These options, totalling 23,750,000, were issued on 27 January 2023 along with a further 26,250,000

## Notes to the Financial Statements (continued)

options attaching to a placement of 52,500,000 shares at an issue price of \$0.01. Further, the arranging broker was issued with 6,000,000 shares and 3,000,000 options on 27 January 2023. The result was a total of 53,000,000 options were issued on 27 January 2023.

	Date	Number of shares	\$
<b>31 December 2021 movements in issued capital:</b>			
Balance at 1 January 2021		152,138,505	14,211,972
Placement at \$0.045 per share (i)	3 Sep 2021	30,000,000	1,350,000
Entitlement issue at \$0.045 per share (ii)	5 Oct 2021	11,805,730	531,258
Conversion performance rights (see Note 7)			
- 50% of Tranche D, at \$0.07 per share	29 Jan 2021	221,500	15,505
- Tranche M, at \$0.053 per share	11 Nov 2021	500,000	26,500
Shares issued under an equity agreement (see Note 14)			
- Shares issued under the equity facility, at \$0.05 per share	6 Jan 2021	4,000,000	200,000
- Shares issued under the equity facility, at \$0.045 per share	6 Apr 2021	5,000,000	230,000
- Shares issued under the equity facility, at \$0.037 per share	12 Nov 2021	5,405,405	200,000
- Payment for collateral shares, at \$0.046 per share	6 Apr 2021	-	161,000
		<u>209,071,140</u>	<u>16,926,235</u>
Share issue expenses		-	(156,796)
Balance at 31 December 2021		<u>209,071,140</u>	<u>16,769,439</u>

- (i) Each 2 participating shares entitled the participant to 1 option with an exercise price of \$0.058 with a 2 year term. These options, totalling 15,000,000, were issued on 1 February 2022. Further, the arranging broker was issued with 1,000,000 with an exercise price of \$0.058 on or before 6 September 2021.
- (ii) Each 2 participating shares entitled the participant to 1 option with an exercise price of \$0.058 with an expiry date of 5 October 2021.

The holders of ordinary shares are entitled to participate in dividends and the proceeds on winding up of the Company. On a show of hands at meetings of the Company, each holder of ordinary shares has one vote in person or by proxy, and upon a poll each share is entitled to one vote. The Company does not have authorised capital or par value in respect of its shares.

### (b) Share options

#### *Options issued and exercised:*

During 2022, the following options were issued as part of an amendment to an equity finance facility (see Note 13 for details):

Expiry Date	Exercise Price	Number Issued	Number Exercised	Number Remaining at 31 December 2022
4 Oct 2025	2.0 cents	7,500,000	-	7,500,000

During 2021, the following options were issued as part of a capital raising (see Notes 14 for further details):

Expiry Date	Exercise Price	Number Issued	Number Exercised	Number Remaining at 31 December 2021
6 Sep 2023	5.8 cents	1,000,000	-	1,000,000
1 Feb 2024	5.8 cents	15,000,000	-	15,000,000
5 Oct 2023	5.8 cents	5,902,855	-	5,902,855

No options were exercised during either the 2022 or 2021 years.

## Notes to the Financial Statements (continued)

### Options on issue:

Unissued ordinary shares of the Company under option:

Terms of Options	Number on Issue at 31 Dec 2022	Number on Issue at 31 Dec 2021
Unlisted options with an exercise price of \$0.10 on or before 22 Dec 2022, expired unexercised	-	3,300,000
Unlisted options with an exercise price of \$0.1018 on or before 28 Oct 2023	3,900,000	3,900,000
Unlisted options with an exercise price of \$0.058 on or before 6 Sep 2023	1,000,000	1,000,000
Unlisted options with an exercise price of \$0.058 on or before 1 Feb 2024	15,000,000	15,000,000
Unlisted options with an exercise price of \$0.058 on or before 5 Oct 2023	5,902,855	5,902,855
Unlisted options with an exercise price of \$0.02 on or before 4 October 2025, see Note 13	7,500,000	-
<b>Total</b>	<b>33,302,855</b>	<b>29,102,855</b>

### Weighted average exercise prices:

The following table illustrates the number (No.) and weighted average exercise prices of and movements in share options issued as compensation during 2022 and 2021:

	2022 No	2022 Weighted average exercise price	2021 No	2021 Weighted average exercise price
Outstanding at the beginning of the year	29,102,855	6.9 cents	9,431,328	12 cents
Granted during the year	7,500,000	0.2 cents	21,902,855	5.8 cents
Forfeited during the year	-	-	2,081,328	20 cents
Exercised during the year	-	-	-	-
Expired during the year	(3,300,000)	\$0.10	-	-
Outstanding at the end of the year	33,302,855	5.5 cents	29,102,855	6.9 cents
Exercisable at the end of the year	33,302,855	5.5 cents	29,102,855	6.9 cents

### Valuation of options

Options were valued using a Black Scholes Option Pricing model. The fair value of Options is recognised as an expense at the date of issue using the following assumptions:

Grant Date	Number Issued	Exercise Price (cents)	Assumed Stock Price at Grant Date (cents)	Interest Rate	Volatility	Value Per Option (cents)
6/9/2021	1,000,000	5.8	4.5	0.8%	100%	2.1
13/10/2022	7,500,000	2.0	0.9	3.4%	80%	0.8

In 2022, \$36,849 was recognised as finance cost. See Note 13 for further details of the options issued.

The amount recognised as a share issue expense for Options issued during the 2021 year was \$20,760.

## Notes to the Financial Statements (continued)

### (c) Performance rights

The following is a summary of the performance rights over the year:

Tranche	Performance Hurdle	Opening	Granted	Expired	Converted	Closing
C	Completion of iPhone Series X production of at least 100,000 units	223,000	-	-	-	223,000
D	Completion of production of the first three Android models of at least 100,000 units	217,500	-	-	-	217,500
E	12 months from completion of gaming software development kit or launch of first five 3D games introduced to market	434,000	-	-	-	434,000
F	Securing distribution in China with sales of at least 100,000 units	610,000	-	-	-	610,000
K	A\$8m of sales revenue across all by 31 December 2022 as validated from audited / reviewed financial reports	2,710,000	-	(2,710,000)	-	-
L	A\$15m of sales revenue across all by 31 December 2023 as validated from audited / reviewed financial reports	2,260,000	-	-	-	2,260,000
M	The Company securing exclusive commercial and marketing rights of all antiviral products developed by Innov Limited by 31 December 2021 as validated by an exclusive licencing agreement	500,000	-	-	(500,000)	-
O	A\$2.7m of EyeFyx product sales revenue by 31 December 2022 as validated from audited / reviewed financial reports	250,000	-	(250,000)	-	-
P	A\$5m of EyeFyx product sales revenue by 31 December 2023 as validated from audited / reviewed financial reports	250,000	-	-	-	250,000
Total		7,454,500	-	(2,960,000)	(500,000)	3,994,500

50% of each tranche of Performance Rights vest on achievement of the respective performance hurdle and 50% vest 12 months after achievement of the respective hurdle as long as the respective staff member continuously remains employed by the Company 12 months after achievement of the respective hurdle.

The shares to be issued in the event of vesting of the Performance Rights shall rank pari-passu in all respects with other fully paid ordinary shares in the Company.

Any unvested Performance Rights will lapse 7 years after their date of issue or if the respective performance hurdle is not achieved by the date specified, where applicable.

The shares to be issued in the event of vesting of the Performance Rights shall rank pari-passu in all respects with other fully paid ordinary shares in the Company.

Any unvested Performance Rights will lapse 7 years after their date of issue or if the respective performance hurdle is not achieved by the date specified, where applicable.

The probability of achievement of the performance rights has been set at nil for 2022 which resulted in the reversal of the previous share based payment expense of \$100,922.

#### *Valuation of Performance Rights*

Performance Rights are valued at the last price at which a share in the Company traded on the Australian Securities Exchange.

## Notes to the Financial Statements (continued)

The fair value of Performance Rights is recognised as an expense over the period from grant to vesting date assuming the performance hurdle has been achieved.

The following table lists the assumptions to the model used to value performance rights for the year ended 31 December 2021.

Number Issued	Grant Date	Assumed Stock Price at Grant Date (cents)	Issue Price (cents)	Value Per Performance Share (cents)
8,930,000	31/3/2021	5.3	nil	5.3

The performance rights have a 7 year expiry date. The date at which the performance hurdle is assumed to be achieved has been estimated based on the target date for the performance hurdle to be achieved. If the milestone is not satisfied on or before expected achievement dates, the Performance Rights will expire.

For remuneration and expense recognition purposes the value is the number of performance rights granted, multiplied by the share price at date of grant and the value being amortised over the period to the expected vesting date after assessing the likelihood, probability and date of achieving these milestones. These are then reassessed at each reporting date for performance rights which have not been achieved nor expired.

### 15. RELATED PARTIES

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

#### (a) Subsidiaries

The consolidated financial statements include the financial statements of Nanoveu Limited and the subsidiaries listed in the following table:

Name	Country of Incorporation	% Equity interest 2022	% Equity interest 2021
Nanoveu Pte Ltd	Singapore	100%	100%
Nanoveu Distribution Inc	USA	100%	100%

#### The Group's related parties are as follows:

##### (i) Key management personnel ('KMP'):

Any person(s) having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including any director (whether executive or otherwise) of that Group are considered key management personnel.

For details of remuneration disclosures relating to key management personnel, refer to Note 17: Key Management Personnel Disclosures.

Other transactions with KMP and their related entities are shown below.

##### (ii) Other related parties include close family members of key management personnel and entities that are controlled or significantly influenced by those key management personnel or their close family members.

##### (iii) Apart from reimbursements for expenses paid on behalf of the Group, director and fees paid directly or indirectly to director related entities, there were no transactions or balances with KMP during the years ended 31 December 2022 and 2021.

## Notes to the Financial Statements (continued)

### 16. KEY MANAGEMENT PERSONNEL

	2022	2021
	\$	\$
<i>Remuneration paid:</i>		
Short-term employee benefits	409,347	465,204
Post-employment benefits	27,460	30,466
Share-based payments	-	(150,994)
Non-monetary benefits – directors’ and officers’ insurance	20,441	20,440
	<u>457,248</u>	<u>365,116</u>

Please see the Remuneration Report for further details.

### 17. PARENT ENTITY INFORMATION

#### (a) Information relating to Nanoveu Limited

	2022	2021
	\$	\$
Current assets	69,304	1,810,851
Non-current assets	-	-
Total assets	<u>69,304</u>	<u>1,810,851</u>
Current liabilities	418,974	1,037,476
Non-current liabilities	-	-
Total liabilities	<u>418,974</u>	<u>1,037,476</u>
Net assets	<u>(349,670)</u>	<u>773,375</u>
Contributed equity	17,423,425	16,605,178
Reserves	783,107	565,353
Accumulated losses	<u>(18,556,202)</u>	<u>(16,397,156)</u>
Total shareholders’ equity	<u>(349,670)</u>	<u>773,375</u>
Loss for the parent entity	<u>(2,159,046)</u>	<u>(2,280,045)</u>
Total comprehensive income of the parent entity	<u>(2,159,046)</u>	<u>(2,280,045)</u>

#### (b) Guarantees

No guarantees have been entered into by the Company in relation to the debts of its subsidiaries. As at 31 December 2022 the parent entity had no contingent liabilities.

#### (c) Commitments

Commitments of the Company as at reporting date are disclosed in note 19 to the financial statements.

### 18. COMMITMENTS

The Group does not have any commitments not disclosed elsewhere in these financial statements.

## Notes to the Financial Statements (continued)

### 19. FINANCIAL RISK MANAGEMENT

The Group's financial situation is not complex. Its activities may expose it to a variety of financial risks in the future: market risk (including currency risk and fair value interest rate risk), credit risk, liquidity risk and cash flow interest rate risk. At that stage the Group's overall risk management program will focus on the unpredictability of the financial markets and seek to minimise potential adverse effects on the financial performance of the Group.

The Group holds the following financial assets and liabilities:

	2022	2021
	\$	\$
<b>Financial Assets</b>		
Cash and cash equivalents	248,142	2,013,375
Trade and other receivables	23,831	205,961
	<u>271,973</u>	<u>2,219,336</u>
<b>Financial Liabilities</b>		
Trade and other payables	379,775	161,409
Financial liability	300,000	986,682
	<u>679,775</u>	<u>1,148,091</u>

#### (a) Market risk

##### *Cash flow and fair value interest rate risk*

The Group's main interest rate risk arises from cash and cash deposits. Deposits at variable rates expose the Group to cash flow interest rate risk. Deposits at fixed rates expose the Group to fair value interest rate risk. During the period, the Group's deposits at variable rates were denominated in Australian and Singaporean Dollars. The Group does not use derivatives to mitigate these exposures.

As at the reporting date, the Group had the following variable rate deposits and there were no interest rate swap contracts outstanding:

	2022 weighted average interest rate %	2022 Balance \$	2021 weighted average interest rate %	2021 Balance \$
Cash and cash equivalents	0.01%	248,142	0.01%	2,013,375
Trade receivables	-	23,831	-	65,671
Net exposure to cash flow interest rate risk		<u>271,973</u>		<u>2,079,046</u>

The Group adopts a policy of ensuring that as far as possible it maintains excess cash and cash equivalents in high bearing accounts.

##### *Sensitivity*

During the period, if interest rates had been 50 basis points higher or lower than the prevailing rates realised, with all other variables held constant, there would be an immaterial change in post-tax profit for the year.

##### *Foreign currency risk*

The Group is exposed to currency risk primarily through having operations in Singapore and the United States which incur expenses denominated in a currency other than the reporting currency. The currency giving rise to this risk is United States Dollars.

The following table details the Group's exposure at the reporting date to currency risk arising from recognised liabilities denominated in United States Dollars.

## Notes to the Financial Statements (continued)

	2022	2021
	\$	\$
Trade and other payables	379,775	161,409
	<u>379,775</u>	<u>161,409</u>

### Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in United States Dollars exchange rates, with all other variables held constant. The impact on the Group's profit before tax is due to changes in the fair value of monetary assets and liabilities including embedded derivatives.

	Change in SGD and USD Exchange Rates	Effect on Profit Before Tax	Effect on Equity
2022	+10%	(35,226)	-
	-10%	35,226	-
2021	+10%	(12,354)	-
	-10%	12,354	-

The movement in the pre-tax effect is a result of a change in the fair value of monetary assets and liabilities denominated in USD.

### (b) Credit risk

The Group has no significant concentrations of credit risk. Cash transactions are limited to high credit quality financial institutions, being major banks in Australia and Singapore.

Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as credit exposures on outstanding receivables and committed transactions. In relation to other credit risk areas management assesses the credit quality of the customer, taking into account its financial position, past experience and other factors.

At the reporting date, there are no impaired trade receivables, and no trade receivables past due but not impaired.

The maximum exposure to credit risk at the reporting date is the carrying amount of the financial assets as summarised at the beginning of this note.

### (c) Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. The Group will aim at maintaining flexibility in funding by accessing appropriate committed credit lines available from different counterparties where appropriate and possible. Surplus funds when available are generally only invested in high credit quality financial institutions in highly liquid markets.

The carrying value of trade and other payables is deemed to represent contractual cashflows due to their short term maturity. Financial liabilities are valued based on contractual cashflow.

### (d) Capital Risk Management

The Group manages its capital to ensure that it will be able to continue as a going concern while maximising the return to shareholders. The capital structure of the Group consists of equity attributable to equity holders, comprising issued capital and accumulated losses.

## Notes to the Financial Statements (continued)

The Board reviews the capital structure on a regular basis and considers the cost of capital and the risks associated with each class of capital. The Group will balance its overall capital structure through new share issues as well as the issue of debt, if the need arises.

### 20. AUDITORS' REMUNERATION

	2022	2021
	\$	\$
Amounts received or due and receivable by the auditors for:		
- Auditing or reviewing the financial report		
o BDO Audit (WA) Pty Ltd	33,000	33,000
o Other auditors	8,849	4,314
	<u>41,849</u>	<u>37,314</u>

### 21. EVENTS AFTER THE REPORTING DATE

Subsequent to year end, and following approval by shareholders, \$525,000 was raised from the issue of 52,500,000 shares at \$0.01 per share, and 50,000,000 options with an exercise price of \$0.02 each on or before 26 January 2026 were issued.

62 Capital Pty Ltd acted as the lead manager and subsequent to year end were issued 6,000,000 shares and 3,000,000 options with an exercise price of \$0.02 on or before 26 January 2026.

Other than the matters noted above, there has not arisen in the interval between the end of the financial period and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the Directors of the Company, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group in future.

## DIRECTORS' DECLARATION

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 2 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 31 December 2022 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



**Alfred Chong**

**Managing Director and CEO**

28 February 2023

## INDEPENDENT AUDITOR'S REPORT

To the members of Nanoveu Limited

### Report on the Audit of the Financial Report

#### Opinion

We have audited the financial report of Nanoveu Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies and the directors' declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the *Corporations Act 2001*, including:

- (i) Giving a true and fair view of the Group's financial position as at 31 December 2022 and of its financial performance for the year ended on that date; and
- (ii) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

#### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

For personal use only

### Material uncertainty related to going concern

We draw attention to Note 2.3 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the group's ability to continue as a going concern and therefore the group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our opinion is not modified in respect of this matter.

### Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the *Material uncertainty related to going concern* section, we have determined the matters described below to be the key audit matters to be communicated in our report.

### Accounting for Share Purchase Subscription Agreement

<i>Key audit matter</i>	<i>How the matter was addressed in our audit</i>
<p>During the year Nanoveu Limited modified its share purchase subscription agreement with Antiviral Technologies Portfolio, LLC ("the Investor"). Refer Note 13 in the financial report for further details.</p> <p>We have identified the accounting for the modification to the share purchase subscription agreement as a key audit matter due to the quantum of the facility in addition to the complexity and judgements involved in assessing the modification of the agreement which can have a significant effect on the appropriate classification and resulting accounting for the facility.</p>	<p>Our audit procedures in this area included, but were not limited to:</p> <ul style="list-style-type: none"> <li>• Holding discussions with management and reviewing the Share Placement Term Sheet and amendment entered into during the year to understand the key terms and conditions of the transaction;</li> <li>• Inspecting Board minutes and other appropriate documentation to assess whether the transactions were appropriately authorised;</li> <li>• Assessing whether management's assessment of the modification of the agreement and subsequent accounting was in accordance with accounting standards;</li> <li>• Reviewing management's calculations carried out in respect of the facility; and</li> <li>• Assessing the adequacy of the related disclosures in the financial report.</li> </ul>

For personal use only

## Other information

The directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 31 December 2022, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at:

[https://www.auasb.gov.au/admin/file/content102/c3/ar1\\_2020.pdf](https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf)

This description forms part of our auditor's report.

## Report on the Remuneration Report

### Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 12 to 19 of the directors' report for the year ended 31 December 2022.

In our opinion, the Remuneration Report of Nanoveu Limited, for the year ended 31 December 2022, complies with section 300A of the *Corporations Act 2001*.

### Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO Audit (WA) Pty Ltd

A handwritten signature in blue ink that reads 'BDO'.A handwritten signature in blue ink that reads 'JW'.

Jackson Wheeler

Director

Perth

28 February 2023

For personal use only

## ASX ADDITIONAL INFORMATION

Additional information required by the Australian Stock Exchange Ltd and not shown elsewhere in this report is as follows. The information is current as at 22 February 2023.

### (a) Distribution of equity securities

The number of security holders by size of holding in each class are:

	Quoted Fully Paid Ordinary Shares	Unquoted Options 28/10/23 Expiry, \$0.1018 Exercise	Unquoted Options 6/9/23 Expiry, \$0.058 Exercise	Unquoted Options 5/10/23 Expiry, \$0.058 Exercise	Unquoted Options 1/2/24 Expiry, \$0.058 Exercise	Unquoted Options 4/10/25 Expiry, \$0.02 Exercise	Unquoted Options 27/1/26 Expiry, \$0.02 Exercise
1 - 1,000	20	-	-	6	-	-	-
1,001 - 5,000	36	-	-	28	-	-	-
5,001 - 10,000	153	-	-	12	-	-	-
10,001 - 100,000	391	-	-	18	10	-	-
> 100,000	205	1	1	14	26	1	11
<b>Totals</b>	<b>805</b>	<b>1</b>	<b>1</b>	<b>78</b>	<b>36</b>	<b>1</b>	<b>11</b>

### (b) Substantial shareholders

The names of the substantial shareholders disclosed to the Company as substantial shareholders are:

#### Ordinary shareholders

Holder Name	Number	%
MR SUFIAN AHMAD	45,946,887	13.54%
MR TECK ENG CHONG	43,007,558	12.68%
MR BILAL AHMAD	37,250,000	10.98%

### (c) Unmarketable parcels

There were 419 holders, with a total share holding of 5,573,840 ordinary shares, of less than a marketable parcel of ordinary shares.

## ASX ADDITIONAL INFORMATION

### (d) Twenty largest holders of quoted equity securities

Position	Holder Name	Holding	% IC
1	MR SUFIAN AHMAD <SIXTY TWO CAPITAL A/C>	45,946,887	13.54%
2	MR TECK ENG CHONG	43,007,558	12.68%
3	MR BILAL AHMAD	37,250,000	10.98%
4	BNP PARIBAS NOMS PTY LTD <DRP>	15,379,425	4.53%
5	KOBALA INVESTMENTS PTY LTD <FERNANDO EDWARD FAMILY A/C>	14,480,362	4.27%
6	CLAYTON CAPITAL PTY LTD	14,132,650	4.17%
7	DR ROSAMUND JULIAN BANYARD & MR PHILLIP STANLEY HOLTEN <R BANYARD SUPER FUND A/C>	12,816,563	3.78%
8	CITICORP NOMINEES PTY LIMITED	7,939,993	2.34%
9	MR AHMED NOMAN	5,625,966	1.66%
10	MR SIAVASH KHOSROWSHAHI & MRS ZAHRA-NAHID KHOSROWSHAHI <S KHOSROWSHAHI FAMILY A/C>	5,450,000	1.61%
11	HENDRIK ANTOON LIMITED	5,345,438	1.58%
12	MR ROBERT ANTHONY MARTIN <MARTIN FAMILY A/C>	5,000,000	1.47%
12	MR DEAN BRETT BLANKFIELD <DEAN BLANKFIELD A/C>	5,000,000	1.47%
13	MR MOBEEN IQBAL	4,600,000	1.36%
14	MR COREY JAY SANDERS	3,874,466	1.14%
15	TANTULA PTY LTD <EDWARDS FAMILY S/F A/C>	3,857,349	1.14%
16	MR SUFIAN AHMAD	3,500,000	1.03%
17	NETWEALTH INVESTMENTS LIMITED <WRAP SERVICES A/C>	2,729,446	0.80%
18	ANDREA CHEAH WERN LI	2,467,063	0.73%
19	J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	2,331,782	0.69%
20	MR ALAN TRAVINE SYMONS	2,251,470	0.66%
	<b>Total</b>	<b>242,986,418</b>	<b>71.62%</b>
	<b>Total issued capital - selected security class(es)</b>	<b>339,270,275</b>	<b>100.00%</b>

## ASX ADDITIONAL INFORMATION

### (e) Unquoted equity securities shareholdings greater than 20%

Class and Holder Name	Holding	%
<u>Unlisted options, \$0.1018 exercise, 28 October 2023 expiry</u>		
ATLANTIC CAPITAL HOLDINGS PTY LTD <ATLANTIC CAPITAL A/C>	3,300,000	100.00%
<u>Unlisted options, \$0.058 exercise, 6 September 2023 expiry</u>		
SAR CAPITAL PTY LTD <SAR FAMILY A/C>	500,000	50.00%
CASTLEREAGH PARTNERS PTY LTD	500,000	50.00%
<u>Unlisted options, \$0.058 exercise, 5 October 2023 expiry</u>		
BNP PARIBAS NOMS PTY LTD <DRP>	1,272,750	21.56%
<u>Unlisted options, \$0.02 exercise, 4 October 2025 expiry</u>		
BERGEN GLOBAL OPPORTUNITY FUND	7,500,000	100.00%
<u>Unlisted options, \$0.02 exercise, 27 January 2026 expiry</u>		
MR SUFIAN AHMAD	21,725,000	41.00%

### (f) Additional ASX Required Disclosures not Made Elsewhere

In accordance with Listing Rule 4.10, the Company confirms there is no current on-market share buy-back.